Aussies find new combo to tackle deadly cancer

After wowing ESMO last month, Australian researchers have found another combo including Amgen's Imdelltra could amplify the immune response in patients with small cell lung cancer (SCLC), the most aggressive form of the disease which has a five-year survival rate of less than seven percent.